Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 11, 2018

Study Completion Date

September 11, 2018

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Ezutromid

Administered orally.

Trial Locations (16)

Unknown

UCLA-David Geffen School of Medicine, Los Angeles

Children's Hosptial of Colorado, Aurora

Nemours Children's Clinic, Orlando

Boston Children's Hospital, Boston

Cincinnati Children's Hospital Medical Center, Cincinnati

Oregon Health and Science University, Portland

Children's Hospital of Philadelphia, Philadelphia

Vanderbilt University Medical Center, Nashville

University of Utah Hospital and Clinics, Salt Lake City

Heart of England NHS Foundation Trust - Heartlands Hospital, Birmingham

Bristol Children's Hospital, Bristol

Addenbrooke's Hospital, Cambridge

Alder Hey Children's NHS Foundation Trust, Liverpool

Great Ormond Street Hospital for Children NHS Foundation Trust, London

Royal Manchester Children's Hospital - Central Manchester University Hospitals NHS Foundation Trust, Manchester

The Freeman Hospital, Newcastle Upon Tyne Hospitals, Newcastle

Sponsors
All Listed Sponsors
lead

Summit Therapeutics

INDUSTRY

NCT02858362 - Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter